Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

231.52
-0.8300-0.36%
Post-market: 227.76-3.7600-1.62%19:30 EDT
Volume:1.00M
Turnover:233.31M
Market Cap:15.03B
PE:15.83
High:236.00
Open:231.60
Low:230.39
Close:232.35
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.24
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.13
PE(LYR):-39.64

Loading ...

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals price target raised to $281 from $264 at Truist

TIPRANKS
·
Aug 26

Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Aug 26

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 26

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

TIPRANKS
·
Aug 26

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Aug 26

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $281 from $264

THOMSON REUTERS
·
Aug 26

Jazz Pharma Says FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

Reuters
·
Aug 25

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Includes Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 25

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) with and Without Tislelizumab Plus Chemotherapy in First-Line Her2+ Advanced Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Aug 25

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative

Simply Wall St.
·
Aug 21

Jazz Pharmaceuticals Advances Phase 3 Xywav Dosing Study in Sleep Disorders

TIPRANKS
·
Aug 20

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19